library_construction_protocol: Three million human chronic myeloid leukemia K562 cells were seeded at 1 million cells per 1 ml of culture medium in each well of 6-well plates. The cells were grown in RPMI 1640 (Gibco, Billings, MT, USA) supplemented with 10% heat-inactivated fetal bovine serum (ExCell Bio, Montevideo, Uruguay) and 1% penicillin-streptomycin (Gibco) at 37 oC in 5% CO2. After 16 h, the cells were separately treated with 0.1%DMSO, 100 μM etoposide (AbMole), 100 μM teniposide (Merck), 10 μM mitoxantrone (Merck), 10 μM m-amsacrine hydrochloride (Merck), 10 μM pixentrone, 0.1 μM, 1 μM, 10 μM, 20 μM or 100 μM doxorubicin (Merck), and 20 μM epirubicin (Selleck) for 1 hour. All drugs were dissolved in DMSO, and each treatment was done in three independent biological replicas. After the drug treatment, DNA was isolated with the TIANamp Genomic DNA Kit (TIANGEN Biotech, DP304) according to the manufacturer's protocol SSiNGLe method